sglt2 inhibitors and glp 1 agonist Cardiorenal Protection: Potential of GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes | Diabetes Therapy How Do SGLT2 (Sodium-Glucose Cotransporter
Description
Already, many GLP-1 users quit within a year, studies suggest often due to side effects, high costs, or insurance issues
In terms of safety, there was no evidence of diabetic ketoacidosis or severe hypoglycemia with acmopatide
You may have heard this
At DevotedDOc , telehealth also makes it easier to stay connected with your care team
Lancet 384 , 13491357 (2014)
30031-7/asset/bedae7b4-4f80-4686-b4c7-9c3f908ac1bd/main.assets/gr1.jpg)
Moreover, GLP-1R activation counteracts the effects of -adrenoceptor stimulation on cardiac ventricular excitability and reduces ventricular arrhythmic potential [165]
